| ￥3000 | |
| Z05354-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95%?as?determined?by?Bis?Tris?PAGE? > 95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 38.91 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of GIPR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. ?
GIPR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. ?
| Target Background | The gastric inhibitory polypeptide receptor (GIPR), a G protein-coupled receptor (GPCR) that regulates glucose metabolism and insulin secretion, is a target for the development of therapeutic agents to address type 2 diabetes and obesity. |
| Synonyms | GIP-R; GIPR; PGQTL2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
